National Health Research Institutes (NHRI) and Applied BioPharma LLC have signed the technology transfer agreement on May, 2021. Applied Biopharma is a wholly owned subsidiary by Agentix Corp. (OTC: AGTX) and has granted the exclusive rights of the antidiabetic drug, DBPR211, with global patents.
About DBPR211
Developed by IBPR, DBPR211 is a potent antagonist selectively acting on the peripheral cannabinoid receptor type 1 (CB1) receptors which had received IND approvals from the US FDA and Taiwan FDA in 2016 and 2017, respectively.
About Agentix
AGENTIX is a vertically integrated company focused on the development and commercialization of both established cannabinoid pharmaceuticals, leveraging molecules already approved for pharmaceutical applications with lower clinical risks and shorter timelines to market, as well as novel, science-driven, synthetic cannabinoid biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas with greater market exclusivity. For more information, please visit www.agentixcorp.com
About IBPR of the NHRI
Institute of Biotechnology and Pharmaceutical Research of the NHRI is a mission-driven drug discovery and development engine with vertical and horizontal coordination and integration. For more information, visit https://ibpr.nhri.org.tw/en/ .
Related News:
Link 2:https://finance.yahoo.com/news/agentix-corporation-national-health-research-120000896.html
More from my site
The novel smallmolecule anticancer drug candidate licensed to SynCore Biotechnology has been approved for the Phase II clinical trial by TFDA and US FDA
NHRI licenses DBPR216, an anti-cancer developmental drug candidate, to Taivex Therapeutics Corp
Congratulations to the team that leads the project: ‘’The discovery and development of a novel small-molecule Hepatitis C virus inhibitor, DBPR110’’ from IBPR for receiving the 2016 Technology Transfer Award – Silver Medal Award by Taipei City Government.
Congratulation to Dr. Hsing-Pang Hsieh, Investigator of IBPR, on receiving 2015 NHRI Outstanding Research Achievement Award.
The National Health Research Institutes (NHRI) and Molecular Targeting Technologies Inc. co-published the results of the cooperation on new anti-cancer therapeutics at the American Association for Cancer Research (AACR) meeting 2015
DBPR211, a novel small-molecule anti-type 2 diabetes drug candidate, was approved for Phase I clinical study by the US Food and Drug Administration (FDA)